Resistance to doxorubicin in tumor cells in vitro and in vivo after pretreatment with verapamil.
Sarcoma 180 (S180) cells pretreated with verapamil increase their resistance to doxorubicin in vitro. This result could be confirmed by in vivo experiments using P388 cells. The mechanism for this resistance is different from the P-glycoprotein-mediated mechanism characteristic for multidrug-resistant cells.